- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Adalimumab – March 2016
Adalimumab: 40 mg/0.8 mL injection, 2 x 0.8 mL cartridges 40 mg/0.8 mL injection, 2 x 0.8 mL syringes 40 mg/0.8 mL injection, 6 x 0.8 mL cartridges 40 mg/0.8 mL injection, 6 x 0.8 mL syringes, Humira®
Last updated
15 July 2016
